Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study on Improving Burn Scars with Adipose-Derived Stem Cells and Autologous Stromal Vascular Fraction for Patients with Hypertrophic Scarring

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a new treatment for hypertrophic scarring, which is a type of thick, raised scar that can develop after a burn injury. The study will explore the use of adipose-derived stem cells and autologous stromal vascular fraction to improve the quality of these scars. Adipose-derived stem cells are special cells taken from fat tissue, while autologous stromal vascular fraction involves using a patient's own fat tissue to obtain cells that may help in healing.

The purpose of the study is to investigate whether these treatments can improve scar quality compared to a placebo. Participants will receive injections of either the stem cells, the stromal vascular fraction, or a placebo into their scar tissue. The study will monitor changes in the appearance and structure of the scars over time, using various methods to assess improvements.

Throughout the study, the safety of the treatments will be closely monitored, and any side effects will be documented. The trial aims to provide valuable insights into the potential benefits of using these cell-based therapies for treating hypertrophic scars, which could lead to better outcomes for individuals with burn injuries.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, you will attend an initial visit where the study team will explain the trial process. You will be asked to provide informed consent, confirming your understanding and willingness to participate.

    During this visit, your eligibility will be confirmed based on criteria such as age, scar characteristics, and overall health.

  2. Step 2

    Baseline assessment

    A baseline assessment will be conducted to evaluate your current scar condition. This includes measurements of scar volume, thickness, and appearance using photography and ultrasound.

    You will also undergo a biopsy, which involves taking a small sample of scar tissue for further analysis.

  3. Step 3

    Treatment administration

    You will receive an injection of the study treatment into the scar tissue. The treatment involves the use of adipose-derived regenerative cells (ADRC001) or autologous stromal vascular fraction.

    The injection is administered intradermally, meaning it is injected into the skin. The exact dosage and frequency will be determined by the study protocol.

  4. Step 4

    Follow-up visits

    You will attend regular follow-up visits to monitor the effects of the treatment. These visits will include assessments similar to the baseline assessment, such as photography and ultrasound of the scar.

    The study team will also monitor for any adverse effects or unexpected reactions to the treatment.

  5. Step 5

    Final assessment

    At the end of the study period, a final assessment will be conducted to evaluate changes in your scar condition. This will include the same types of measurements and evaluations as previous assessments.

    The study team will discuss the results with you and provide any necessary follow-up care or recommendations.

Who can join the trial?

5 criteria

  • Adults who are 18 years of age or older.
  • Have hypertrophic scars (thick, raised scars) that are more than 2 years old from burn injuries on the front of the body or limbs.
  • Have three similar areas of burn scar tissue, each measuring 6 cm x 6 cm, on the front of the chest or limbs. The scar should be large enough to have at least two centimeters between these areas.
  • Have a BMI (Body Mass Index) greater than 22 and enough abdominal fat for a small liposuction procedure.
  • Must be able to understand information about the project.

Who cannot join the trial?

4 criteria

  • Patients with **hypertrophic scarring** cannot participate. This means if you have thick, raised scars, you are not eligible.
  • Individuals who are not within the specified age range cannot participate. The study is open to certain age groups only.
  • Both **male** and **female** participants are eligible, but certain conditions may exclude you.
  • Participants who are part of a **vulnerable population** are not eligible. This refers to groups who may need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Allogeneic Adipose-derived Stem Cells

    are special cells taken from the fat tissue of a donor. These cells have the ability to develop into different types of cells and help in healing and repairing damaged tissues. In this trial, they are being used to see if they can improve the quality of scars after a burn injury by promoting better healing and reducing scar tissue formation.

  • Autologous Stromal Vascular Fraction

    is a mixture of cells that is taken from a patient's own fat tissue. This mixture contains various types of cells, including stem cells, which can help in tissue repair and healing. In this trial, the stromal vascular fraction is being used to see if it can improve the appearance and quality of scars after a burn injury by enhancing the body's natural healing processes.

What is already known about the treatment

Adipose-derived Allogeneic Stem Cells – This medication is administered through an injection directly into the affected area, specifically targeting hypertrophic scars that form after burn injuries. Currently, it is being studied in clinical trials to assess its effectiveness in improving scar quality. The main therapeutic use of these stem cells is to enhance the healing and appearance of scars. At the molecular level, these stem cells work by promoting tissue regeneration and reducing inflammation, which helps in remodeling the scar tissue. They are classified under regenerative medicine due to their ability to aid in tissue repair and regeneration.

Investigated diseases

Hypertrophic scar – Hypertrophic scars are raised, thickened areas of skin that form at the site of a wound. They occur when the body produces excess collagen during the healing process. These scars are often red or purple and can be itchy or painful. Unlike keloids, hypertrophic scars do not grow beyond the boundaries of the original wound. Over time, they may become less noticeable but can remain elevated. They are more common in areas of high skin tension, such as the shoulders and chest.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-519160-41-00Estimated enrolment39 patientsSponsorCopenhagen University Hospital

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).